Publication:
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

Simple item page
dc.contributor.authorGavilá, Joaquín
dc.contributor.authorOliveira, Mafalda
dc.contributor.authorPascual, Tomás
dc.contributor.authorPerez-Garcia, Jose
dc.contributor.authorGonzàlez, Xavier
dc.contributor.authorCanes, Jordi
dc.contributor.authorParé, Laia
dc.contributor.authorCalvo, Isabel
dc.contributor.authorCiruelos, Eva
dc.contributor.authorMuñoz, Montserrat
dc.contributor.authorVirizuela, Juan A
dc.contributor.authorRuiz, Isabel
dc.contributor.authorAndrés, Raquel
dc.contributor.authorPerelló, Antonia
dc.contributor.authorMartínez, Jerónimo
dc.contributor.authorMorales, Serafín
dc.contributor.authorMarín-Aguilera, Mercedes
dc.contributor.authorMartínez, Débora
dc.contributor.authorQuero, Juan C
dc.contributor.authorLlombart-Cussac, Antonio
dc.contributor.authorPrat, Aleix
dc.date.accessioned2023-01-25T10:27:37Z
dc.date.available2023-01-25T10:27:37Z
dc.date.issued2019-01-09
dc.identifier.doi10.1186/s12916-018-1233-1
dc.identifier.essn1741-7015
dc.identifier.pmcPMC6325829
dc.identifier.pmid30621698
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325829/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1186/s12916-018-1233-1
dc.identifier.urihttp://hdl.handle.net/10668/13391
dc.issue.number1
dc.journal.titleBMC medicine
dc.journal.titleabbreviationBMC Med
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.page.number8
dc.pubmedtypeClinical Trial, Phase II
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBreast cancer
dc.subjectHER2
dc.subjectHER2-enriched
dc.subjectPAM50
dc.subjectcardiac safety
dc.subjectintrinsic subtypes
dc.subjectneoadjuvant
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBreast Neoplasms
dc.subject.meshCardiotoxicity
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshDoxorubicin
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshNeoadjuvant Therapy
dc.subject.meshPaclitaxel
dc.subject.meshPolyethylene Glycols
dc.subject.meshReceptor, ErbB-2
dc.subject.meshTrastuzumab
dc.titleSafety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number17
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC6325829.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen del Rocío
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía